ACADIA Pharmaceuticals Inc. (ACAD)

In the past six months, ACADIA's stock price has decreased by 0.75%, but has increased by 32.31% over the past year. ACADIA reported Q1 2026 earnings per share of $0.02, missing estimates, and total revenues were $268.1 million, also missing estimates. The successful launch of DAYBUE STIX was highlighted. The company reaffirmed its full-year 2026 revenue guidance of $1.22 billion to $1.28 billion. Selling, general, and administrative expenses rose significantly. Upcoming Phase 2 topline data for remlifanserin and Phase 3 data for trofinetide in Japan are considered significant near-term catalysts.

The provided search results do not offer specific details on the demand seasonality for ACADIA Pharmaceuticals' products and services. The company's products, targeting chronic neurological and rare diseases, may not exhibit strong seasonal demand fluctuations typical of consumer goods, but rather steady demand based on patient diagnoses and ongoing treatment needs.

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. Its primary products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. The company also has a pipeline of product candidates in clinical development, including remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis, ACP-211 for major depressive disorder, ACP-711 for essential tremor, ACP-271 for tardive dyskinesia and Huntington's disease, ACP-2591 for Rett syndrome and Fragile X syndrome, and a STOKE Antisense Oligonucleotide Program for SYNGAP1 syndrome.

ACADIA Pharmaceuticals is headquartered in San Diego, California, and primarily focuses on North America. It also has international programs, including a trofinetide clinical trial in Japan.

ACADIA Pharmaceuticals generally maintains a positive reputation among analysts, with a consensus rating of "Buy" or "Moderate Buy". The successful launch of DAYBUE and the performance of NUPLAZID contribute positively to its reputation. Recent Q1 2026 earnings that missed estimates and increased operating costs have led to some "neutral sentiment" and analyst estimate cuts.

ACADIA Pharmaceuticals' ownership is significantly influenced by institutional investors, including Baker Bros. Advisors Lp, BlackRock, Inc., Vanguard Group Inc, State Street Corp, RTW Investments, L.P., Point72 Asset Management, L.P., and Geode Capital Management, LLC. Felix Baker is a significant insider shareholder.